Table 1.
Baseline clinical characteristics of patients treated with anthracyclines and trastuzumab who developed or did not develop cardiotoxicity
| Cardiotoxicity | |||
|---|---|---|---|
| Variable | Yes (n = 9) |
No (n = 34) |
p Value |
| Age (years) | 47 ± 11 | 49 ± 10 | 0.94 |
| Previous treatment with anthracyclines | 2 (22%) | 8 (23%) | 1.00 |
| Dose of anthracyclines | 1.00 | ||
| Doxorubicin 240 mg/m2 | 9 (100%) | 30 (88%) | |
| Epirubicin 300 mg/m2 | 0 (0%) | 4 (12%) | |
| Treatment with taxanes | 9 (100%) | 34 (100%) | 1.00 |
| Radiotherapy | 2 (22%) | 3 (9%) | 0.28 |
| Side of breast cancer | 1.00 | ||
| Right | 3 (33%) | 14 (41%) | |
| Left | 6 (67%) | 19 (56%) | |
| Both | 0 (0%) | 1 (3%) | |
| Cardiac risk factors | |||
| Blood pressure ≥140/≥90 mm Hg | 2 (22%) | 10 (29%) | 1.00 |
| Total cholesterol >200 mg/dl | 0 (0%) | 8 (23%) | 0.66 |
| Diabetes mellitus | 0 (0%) | 1 (3%) | 1.00 |
| Smoker | 1 (11%) | 5 (15%) | 0.31 |
| Cardiovascular therapy | |||
| Angiotensin-converting enzyme inhibitors | 1 (11%) | 3 (9%) | 0.19 |
| β blockers | 0 (0%) | 3 (9%) | 1.00 |
| Body mass index (kg/m2) | 23 ± 12 | 26 ± 4 | 0.74 |
| Systolic blood pressure (mm Hg) | 120 ± 11 | 122 ± 18 | 0.98 |
| Diastolic blood pressure (mm Hg) | 75 ± 10 | 74 ± 9 | 0.19 |
| Heart rate (beats/min) | 71 ± 11 | 69 ± 9 | 0.38 |
Data are expressed as mean ± SD or as number (percentage).